Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-Mouse RNF43 Polyclonal Antibody

Catalog #:   PMK86001 Specific References (27) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA, IHC, WB
Accession: Q5NCP0
Overview

Catalog No.

PMK86001

Species reactivity

Mouse

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Mouse RNF43 (Gln44-Lys189).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

E3 ubiquitin-protein ligase RNF43, RING finger protein 43, RING-type E3 ubiquitin transferase RNF43, RNF43

Purification

Purified by antigen affinity column.

Accession

Q5NCP0

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Data Image
  • Western Blot
    Recombinant Protein lysates were subjected to SDS PAGE followed by western blot with RNF43 antibody (PMK86001) at 1 μg/ml.

    Lane 1: Recombinant protein

    Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

    Predict MW: 18 kDa
    Observed MW: 18 kDa
References

Structure-Guided Development of Chemically Tailored Peptide Binders of RNF43/ZNRF3 to Enable Versatile Design of Membrane Protein-Targeting PROTACs., PMID:40000409

Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration., PMID:39235609

Targeted protein degradation systems to enhance Wnt signaling., PMID:38847394

DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations., PMID:37992266

Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers., PMID:37482749

Issues with RNF43 antibodies to reliably detect intracellular location., PMID:37023034

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer., PMID:36811382

Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors., PMID:36358851

Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA., PMID:36202008

Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins., PMID:35481357

Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma., PMID:34973294

An Early-Onset Advanced Rectal Cancer Patient With Increased KRAS Gene Copy Number Showed A Primary Resistance to Cetuximab in Combination With Chemotherapy: A Case Report., PMID:34888240

Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1., PMID:33395526

Unlike LGR4, LGR5 potentiates Wnt-β-catenin signaling without sequestering E3 ligases., PMID:33262293

Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer., PMID:33202731

Loss of RNF43 Function Contributes to Gastric Carcinogenesis by Impairing DNA Damage Response., PMID:33188943

Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers., PMID:31949927

Surrogate R-spondins for tissue-specific potentiation of Wnt Signaling., PMID:31914456

RNF43 ubiquitinates and degrades phosphorylated E-cadherin by c-Src to facilitate epithelial-mesenchymal transition in lung adenocarcinoma., PMID:31286874

Anti-LRP5/6 VHHs promote differentiation of Wnt-hypersensitive intestinal stem cells., PMID:30664649

Acquired resistance to immunotherapy in MMR-D pancreatic cancer., PMID:30458888

A synthetic anti-Frizzled antibody engineered for broadened specificity exhibits enhanced anti-tumor properties., PMID:30183492

IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides., PMID:29498403

Molecular genetics and targeted therapy of WNT-related human diseases (Review)., PMID:28731148

Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer., PMID:28266765

Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors., PMID:27869803

Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment., PMID:27341591

Datasheet
$ 170
Product specifications
50 μg 170 100 μg 280

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Mouse RNF43 Polyclonal Antibody [PMK86001]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only